Drug delivery medical device
Provided is a coated implantable medical device, comprising: a substrate; and a coating disposed on the substrate, wherein the coating comprises at least one polymer and at least one pharmaceutical agent in a therapeutically desirable morphology and/or at least one active biological agent and optionally, one or more pharmaceutical carrying agents; wherein substantially all of pharmaceutical agent and/or active biological agent remains within the coating and on the substrate until the implantable device is deployed at an intervention site inside the body of a subject and wherein upon deployment of the medical device in the body of the subject a portion of the pharmaceutical agent and/or active biological agent is delivered at the intervention site along with at least a portion of the polymer and/or a at least a portion of the pharmaceutical carrying agents.
1. A method comprising the steps of
providing a device comprising a balloon; and a coating on at least a portion of the balloon, wherein the coating comprises an active agent, a polymer and a cationic binding agent, wherein the active agent includes a plurality of macrolide immunosuppressive drug particles in crystalline form, some of the particles having a portion uncovered by the polymer and some of the particles being fully encapsulated in the polymer;
inflating the balloon of the device in vivo; and
transferring at least 3% of the active agent and at least a portion of the polymer to a treatment site upon expansion of the balloon in vivo,
wherein the binding agent comprises at least one of: Polyarginine, Polyarginine 9-L-pArg, DEAE-Dextran (Diethylaminoethyl cellulose-Dextran), DMAB (Didodecyldimethylammonium bromide), PEl (Polyethyleneimine), TAB (Tetradodecylammonium bromide), and DMTAB (Dimethylditetradecylammonium bromide).
2. The method of claim 1 , wherein the active agent is sirolimus and wherein the sirolimus has an average size of at least one of: 1.5 μm, 2.5 μm, 645 nm, and 100-200 nm.
3. The method of claim 1 , wherein the coating comprises a 10:1 ratio of the active agent to the binding agent, wherein the active agent comprises sirolimus wherein the binding agent comprises Polyarginine.
4. The method of claim 1 , comprising the step of lyophilizing the active agent and the binding agent prior to depositing the active agent and the binding agent on the balloon.
5. The method of claim 1 , wherein at least about 3 ng/mg of active agent are found in arterial tissue 72 hours after inflation of the balloon in the artery.
6. The method of claim 1 wherein the portion of the balloon having the coating thereon is invertable.
7. The method of claim 1 wherein the device comprises a sheath over the portion of the balloon having coating thereon.
8. The method claim 1 wherein the device comprises an occlude configured to block the flow of bodily fluids at a treatment site during exposure of the coating to the tissue.
9. The method of claim 1 , wherein at least one of: at most 1% of coating is removed from the balloon due to tracking of the coated balloon to the treatment site, at most 5% of coating is removed from the balloon due to tracking of the coated balloon to the treatment site, at most 10% of coating is removed from the balloon due to tracking of the coated balloon to the treatment site, at most 15% of coating is removed from the balloon due to tracking of the coated balloon to the treatment site, at most 20% of coating is removed from the balloon due to tracking of the coated balloon to the treatment site, at most 25% of coating is removed from the balloon due to tracking of the coated balloon to the treatment site, and at most 30% of coating is removed from the balloon due to tracking of the coated balloon to the treatment site.